|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0634 CHF | +0.63% |
|
+16.97% | +54.63% |
| May. 01 | SIX Swiss Exchange Approves Delay in Spexis' FY23 Annual Report Publication | MT |
| Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
Polyphor AG announced that Gkhan Batur, currently Chief Commercial Officer of Polyphor has been appointed as Chief Executive Officer effective immediately. He will succeed Giacomo DiNepi, who will retire after a long-standing and successful career in the Pharmaceutical industry. Gkhan Batur has more than 15 years of healthcare industry experience.
Before joining Polyphor, he assumed various management roles at MSD, most recently serving as Executive Director, Global Brand Leader, Antibiotics.
| 1st Jan change | Capi. | |
|---|---|---|
| +54.63% | 4.73M | |
| -2.61% | 89.08B | |
| +3.55% | 40.9B | |
| -14.40% | 32.25B | |
| +55.89% | 25.14B | |
| -15.96% | 15.39B | |
| -15.50% | 11.91B | |
| -41.29% | 11.89B | |
| -11.75% | 11.64B | |
| +7.87% | 9.03B |
SPEXIS AG 
